Financials data is unavailable for this security.
View more
Year on year abrdn Life Sciences Investors grew revenues 15.89% from 3.02m to 3.50m while net income improved from a loss of 104.60m to a gain of 22.35m.
Gross margin | -36.65% |
---|---|
Net profit margin | 1,067.62% |
Operating margin | -51.94% |
Return on assets | 8.87% |
---|---|
Return on equity | 8.99% |
Return on investment | 8.99% |
More ▼
Cash flow in USDView more
SmartText is unavailable
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 16.13 |
---|---|
Tangible book value per share | 16.13 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 120.48%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg) | -- |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | 91.34% |
EPS growth(5 years) | -8.19 |
---|---|
EPS (TTM) vs TTM 1 year ago | 576.39 |
More ▼